FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients who experience these symptoms should observe caution when driving or using machines.
Croatian: Bolesnici u kojih se jave ti simptomi trebaju biti oprezni pri upravljanju vozilima i radu sa strojevima.
English: If patients miss a dose, they should take their next dose at its regularly scheduled time.
Croatian: Ako bolesnici propuste dozu, sljedeću dozu trebaju uzeti u uobičajeno vrijeme prema rasporedu.
English: However, due to its high permeability and bioavailability, the risk of clinically relevant interactions with medicinal products that inhibit these transporters is unlikely.
Croatian: Ipak, zbog njegove velike permeabilnosti i bioraspoloživosti, vjerojatno nema rizika od klinički važnih interakcija s lijekovima koji inhibiraju ove prijenosnike.
English: Table 5: Secondary endpoints*
Croatian: Tablica 5: Sekundarne mjere ishoda*
English: Women of childbearing potential/contraception in females
Croatian: Žene reproduktivne dobi / kontracepcija u žena
English: Median ages ranged from 57 to 63 years across treatments and cohorts.
Croatian: Medijan dobi bio je u rasponu od 57 do 63 godine po vrstama liječenja i skupinama.
English: Hypertension, including hypertensive crisis
Croatian: Hipertenzija, uključujući hipertenzivnu krizu
English: The absolute bioavailability of niraparib is approximately 73 %, indicating minimal first pass effect.
Croatian: Apsolutna bioraspoloživost nirapariba je približno 73 % što upućuje na minimalan učinak prvog prolaska kroz jetru.
English: This medicinal product contains tartrazine (E 102), which may cause allergic reactions.
Croatian: Ovaj lijek sadrži tartrazin (E 102) koji može uzrokovati alergijske reakcije.
English: Age, weight and race
Croatian: Dob, tjelesna težina i rasa
English: Frequencies of occurrence of undesirable effects are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Croatian: Učestalosti javljanja nuspojava definirane su kao: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≤ 1/1000 i < 1/100); rijetko (≤ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000).
English: Patients were assigned to the gBRCAmut cohort based on blood samples for gBRCA analysis that were taken prior to randomisation.
Croatian: Bolesnici su dodijeljeni u skupinu gBRCAmut na temelju uzoraka krvi za gBRCA analizu uzetih prije randomizacije.
English: Even though inhibition of CYP3A4 in the liver is not expected, the potential to inhibit CYP3A4 at the intestinal level has not been established at relevant niraparib concentrations.
Croatian: Iako se ne očekuje inhibicija CYP3A4 u jetri, mogućnost inhibicije CYP3A4 u crijevima nije ustanovljena pri relevantnim koncentracijama nirapariba.
English: The recommended dose modifications for adverse reactions are listed in Tables 1 and 2.
Croatian: Preporučene modifikacije doza zbog nuspojava navedene su u Tablicama 1 i 2.
English: Pharmacotherapeutic group: other antineoplastic agents, ATC code: L01XX54.
Croatian: Farmakoterapijska skupina: drugi antineoplastički lijekovi, ATK oznaka: L01XX54.
English: Patients could not have received prior PARP inhibitor therapy, including Zejula.
Croatian: Bolesnici prethodno nisu smjeli primati terapiju PARP inhibitorima, uključujući lijek Zejula.
English: Approximately 47 % of patients restarted at a reduced dose in Cycle 2.
Croatian: Približno 47 % bolesnika počelo je ponovo uzimati lijek u smanjenoj dozi u 2. ciklusu.
English: Your doctor may want to test your bone marrow to check for these problems.
Croatian: Vaš će Vam liječnik možda željeti provesti pretrage koštane srži kako bi provjerio imate li te poremećaje.
English: The capsules contain a white to off-white powder.
Croatian: Kapsule sadrže bijeli do bjelkasti prašak.
English: Your doctor will check you on a regular basis, and you will normally continue to take Zejula as long as you experience benefit, and do not suffer unacceptable side effects.
Croatian: Vaš liječnik će Vas redovito kontrolirati, a Vi ćete nastaviti uzimati lijek Zejula dok god budete imali koristi od njega ili dok se ne razviju neprihvatljive nuspojave.
English: The rate of new incidences of thrombocytopenia after intensive dose modifications were performed during the first two months of treatment from Cycle 4 was 1.2 %.
Croatian: Učestalost pojave novih slučajeva trombocitopenije nakon intenzivnih modifikacija doza koje su provedene tijekom prva dva mjeseca liječenja od 4. ciklusa bila je 1,2 %.
English: • Fever or infection - low white blood cell count (neutropenia) can increase your risk for infection.
Croatian: • Vrućica ili infekcija - nizak broj bijelih krvnih stanica (neutropenija) može povećati rizik od infekcije.
English: Animal reproductive and developmental toxicity studies have not been conducted.
Croatian: Ispitivanja reproduktivne i razvojne toksičnosti na životinjama nisu provedena.
English: This medicine contains lactose and tartrazine - see section 2 for more information.
Croatian: Ovaj lijek sadrži laktozu i tartrazin; za više informacija pogledajte dio 2.
English: The CA-125 levels should be normal (or a > 90 % decrease in CA-125 from baseline) following their last platinum treatment, and be stable for at least 7 days.
Croatian: Razine CA-125 morale su biti normalne (ili pasti za > 90 % od početne vrijednosti CA-125) nakon posljednje terapije koja je sadržavala platinu i biti stabilne najmanje 7 dana.
English: Niraparib was moderately protein bound in human plasma (83.0 %), mainly with serum albumin.
Croatian: Niraparib se umjereno vezao za proteine plazme (83,0 %), uglavnom za serumski albumin.
English: It is used after the cancer has responded to previous treatment with standard platinum-based chemotherapy.
Croatian: Koristi se nakon odgovora raka na prethodno liječenje standardnom kemoterapijom koja sadrži platinu.
English: Zejula should not be used during pregnancy.
Croatian: Zejula se ne smije primjenjivati tijekom trudnoće.
English: Zejula contains lactose
Croatian: Zejula sadrži laktozu
English: Only 13 % of low body weight patients remained at a dose of 300 mg beyond Cycle 3.
Croatian: Samo je 13 % bolesnika s malom tjelesnom težinom ostalo na dozi od 300 mg nakon 3. ciklusa.
English: In the case that the adverse reaction recurs, it is recommended to reduce the dose.
Croatian: U slučaju da ponovo dođe do nuspojave, preporučuje se smanjiti dozu.
English: Your doctor will ask you to confirm that you are not pregnant with a pregnancy test before starting your treatment.
Croatian: Vaš će Vas liječnik zamoliti da prije početka liječenja testom na trudnoću potvrdite da niste trudni.
English: Pre-existing hypertension should be adequately controlled before starting Zejula treatment.
Croatian: Prethodno postojeća hipertenzija mora biti odgovarajuće kontrolirana prije početka liječenja lijekom Zejula.
English: Aclar/PVC/aluminium foil perforated unit dose blisters in cartons of 84 × 1, 56 × 1 and 28 × 1 hard capsules.
Croatian: Perforirani blister od Aclar/PVC/aluminijske folije s jediničnim dozama u kutijama od 84 × 1, 56 × 1 i 28 × 1 tvrda kapsula.
English: Radioactive recovery in the urine accounted for 47.5 % (range 33.4 % to 60.2 %) and in the feces for 38.8 % (range 28.3 % to 47.0 %) of the dose.
Croatian: Radioaktivnost pronađena u urinu iznosila je 47,5 % (raspon 33,4 % do 60,2 %), a u fecesu 38,8 % (raspon 28,3 % do 47,0 %) doze.
English: The capsules should be swallowed whole with water.
Croatian: Kapsule treba progutati cijele, s vodom.
English: Do not use this medicine if you notice any damage or signs of tampering to the pack.
Croatian: Ovaj lijek se ne smije upotrijebiti ako primijetite bilo kakvo oštećenje ili pokušaj otvaranja pakiranja.
English: Women of childbearing potential should not become pregnant while on treatment and should not be pregnant at the beginning of treatment.
Croatian: Žene reproduktivne dobi ne smiju zatrudnjeti tijekom liječenja te ne smiju biti trudne na početku liječenja.
English: Zejula should not be taken if you are breast-feeding as it is not known if it passes into breast milk.
Croatian: Zejula se ne smije uzimati ako dojite jer nije poznato prolazi li u majčino mlijeko.
English: Observe caution when driving or using machines.
Croatian: Budite oprezni kada upravljate vozilima i strojevima.
English: Your doctor will measure your blood pressure regularly throughout your treatment.
Croatian: Vaš će Vam liječnik redovito mjeriti krvni tlak tijekom liječenja.
English: Therefore, a clinically meaningful interaction related to an inhibition of these efflux transporters although unlikely, cannot be excluded.
Croatian: Zbog toga, iako klinički značajna interakcija povezana s inhibicijom ovih efluksnih prijenosnika nije vjerojatna, ne može se isključiti.
English: In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death.
Croatian: In vitro ispitivanja pokazala su da citotoksičnost izazvana niraparibom može uključivati inhibiciju enzimatske aktivnosti PARP-a i pojačano stvaranje kompleksa PARP-DNK s posljedičnim oštećenjem DNK, apoptozom i smrću stanice.
English: Testing complete blood counts weekly for the first month, followed by monthly monitoring for the next 10 months of treatment and periodically after this time is recommended to monitor for clinically significant changes in any haematologic parameter during treatment (see section 4.2).
Croatian: Preporučuje se tjedna kontrola kompletne krvne slike tijekom prvog mjeseca, a zatim mjesečna tijekom sljedećih 10 mjeseci liječenja te povremeno nakon tog vremena zbog praćenja klinički značajnih promjena bilo kojeg hematološkog parametra tijekom liječenja (vidjeti dio 4.2).
English: Dose reductions may be implemented based on adverse reactions.
Croatian: Smanjenje doze može se primijeniti na temelju nuspojava.
English: Your doctor may recommend a lower dose if you experience side effects (such as nausea, tiredness, abnormal bleeding/bruising, anaemia).
Croatian: Vaš Vam liječnik može preporučiti nižu dozu ako dođe do nuspojava (kao što su mučnina, umor, abnormalno krvarenje/modrice, anemija).
English: These findings occurred at exposure levels below those seen clinically, and were largely reversible within 4 weeks of cessation of dosing.
Croatian: Ovi su se nalazi javili pri razinama izloženosti ispod onih kliničkih te su velikim dijelom bili reverzibilni unutar 4 tjedna od prestanka primanja doze.
English: No effect on behavioural and/or neurological parameters have been observed in repeat-dose toxicity studies in rats and dogs at estimated CNS exposure levels similar to or below expected therapeutic exposure levels.
Croatian: Nisu bili uočeni učinci na bihevioralne i/ili neurološke parametre u ispitivanjima toksičnosti ponovljenih doza u štakora i pasa pri procijenjenim razinama izloženosti SŽS-a sličnima ili nižima od očekivanih terapijskih razina izloženosti.
English: It is therefore recommended to monitor complete blood counts (CBCs) weekly during the first month of treatment and modify the dose as needed.
Croatian: Zbog toga se preporučuje kontrolirati kompletnu krvnu sliku (KKS) jednom tjedno tijekom prvog mjeseca liječenja te modificirati dozu po potrebi.
English: Effect of other medicinal products on niraparib
Croatian: Utjecaj drugih lijekova na niraparib
English: After the first month, it is recommended to monitor CBCs monthly and periodically after this time (see section 4.4).
Croatian: Nakon prvog mjeseca preporučuje se kontrolirati KKS mjesečno te povremeno nakon tog razdoblja (vidjeti dio 4.4).
English: Grade 3/4 hypertension occurred in 8.2 % of patients.
Croatian: Hipertenzija 3./4. stupnja razvila se u 8,2 % bolesnika.
English: Taking into account the PRAC Assessment Report on the PSUR(s) for niraparib, the scientific conclusions of CHMP are as follows:
Croatian: Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR) za niraparib, znanstveni zaključci CHMP-a su sljedeći:
English: Induction of CYPs (CYP1A2 and CYP3A4)
Croatian: Indukcija CYP enzima (CYP1A2 i CYP3A4)
English: Niraparib is a type of anti-cancer medicine called a PARP inhibitor.
Croatian: Niraparib je vrsta lijeka za rak koji se zove PARP inhibitor.
English: In the pivotal Phase 3 international trial (ENGOT-OV16), the incidence of MDS/AML in patients who received niraparib (1.4 %) was similar to that in patients who received placebo (1.1 %).
Croatian: U međunarodnom pivotalnom ispitivanju faze 3 (ENGOT-OV16), učestalost MDS/AML u bolesnika koji su primali niraparib (1,4 %) bila je slična onoj u bolesnika koji su primali placebo (1,1 %).
English: Each hard capsule shell also contains the colouring agent tartrazine (E 102) [0.0172 mg].
Croatian: Svaka ovojnica tvrde kapsule također sadrži bojilo tartrazin (E 102) [0,0172 mg].
English: This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of niraparib and indicates potential for genotoxicity in humans.
Croatian: Klastogenost je u skladu s nestabilnošću genoma koja je posljedica primarne farmakologije nirapariba i upućuje na moguću genotoksičnost u ljudi.
English: Approximately 25 % of patients in the NOVA study weighed less than 58 kg, and approximately 25 % of patients weighed more than 77 kg.
Croatian: Približno 25 % bolesnika u ispitivanju NOVA imalo je tjelesnu težinu manju od 58 kg, a približno 25 % bolesnika imalo je tjelesnu težinu veću od 77 kg.
English: Hypertension of any grade occurred in 19.3 % of patients treated with Zejula.
Croatian: Hipertenzija bilo kojeg stupnja razvila se u 19,3 % bolesnika liječenih lijekom Zejula.
English: • Decreased appetite
Croatian: • smanjen apetit
English: Patients with ECOG performance status 2 to 4 Clinical data are not available in patients with ECOG performance status 2 to 4.
Croatian: Bolesnici s funkcionalnim statusom 2 do 4 prema ECOG ljestvici Klinički podaci za bolesnike s funkcionalnim statusom 2 do 4 prema ECOG ljestvici nisu dostupni.
English: Most patients were age 18 to 64 years (78 %), Caucasian (86 %) and had an ECOG performance status of 0 (68 %).
Croatian: Većina bolesnika bila je u dobi od 18 do 64 godine (78 %), bili su bijelci (86 %) i imali su funkcionalni status 0 prema ECOG ljestvici (68 %).
English: Anaemia of any grade might persist during Zejula treatment.
Croatian: Anemija bilo kojeg stupnja može perzistirati tijekom liječenja lijekom Zejula.
English: Missing dose
Croatian: Propuštena doza
English: What Zejula is used for
Croatian: Za što se Zejula koristi
English: Treatment with Zejula should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.
Croatian: Liječenje lijekom Zejula treba započeti i nadzirati liječnik s iskustvom u primjeni antineoplastičkih lijekova.
English: • Feeling of worry, nervousness, or unease
Croatian: • osjećaj zabrinutosti, nervoze ili nelagode
English: If you forget to take Zejula
Croatian: Ako ste zaboravili uzeti lijek Zejula
English: If there are other risk factors for bleeding such as co-administration of anticoagulation or antiplatelet medicinal products, consider interrupting these substances and/or transfusion at a higher platelet count.
Croatian: Ako su prisutni i drugi rizični čimbenici za krvarenje, kao što je istodobna primjena antikoagulansa ili antitrombocitnih lijekova, razmotrite privremeni prekid primjene tih lijekova i/ili transfuziju pri većem broju trombocita.
English: In the clinical programme, hypertension was readily managed with anti-hypertensive medicinal products.
Croatian: U kliničkom programu hipertenzija je bila lako zbrinuta antihipertenzivnim lijekovima.
English: • Feeling of weakness
Croatian: • osjećaj slabosti
English: What Zejula is and what it is used for What you need to know before you take Zejula How to take Zejula
Croatian: Što je Zejula i za što se koristi Što morate znati prije nego počnete uzimati lijek Zejula Kako uzimati lijek Zejula
English: However, based on its mechanism of action, niraparib could cause embryonic or foetal harm, including embryo-lethal and teratogenic effects, when administered to a pregnant woman.
Croatian: Međutim, temeljeno na njegovom mehanizmu djelovanja, niraparib bi, primjenjen u trudnica, mogao uzrokovati embrionalna ili fetalna oštećenja, uključujući embrioletalne i teratogene učinke.
English: • Inflammation or swelling of the air passages between the mouth and nose and the lungs,
Croatian: • upalu ili oticanje dišnih puteva između usta i nosa i pluća, bronhitis
English: The most commonly used dose in niraparib-treated patients in the NOVA study was 200 mg.
Croatian: Najčešće primjenjivana doza u bolesnika liječenih niraparibom u ispitivanju NOVA bila je 200 mg.
English: The systemic exposures (Cmax and AUC) to niraparib increased in a dose-proportional manner when the dose of niraparib increased from 30 mg to 400 mg.
Croatian: Sistemska izloženost (Cmax i AUC) niraparibu porasla je proporcionalno dozi kada je doza nirapariba povećana s 30 mg na 400 mg.
English: The primary tumour site in most patients (> 80 %) within each cohort was the ovary; most patients (> 84 %) had tumours with serous histology.
Croatian: Mjesto primarnog tumora u većine je bolesnika (> 80 %) u svakoj skupini bio jajnik; većina bolesnika (> 84 %) imala je, histološki gledano, serozni tumor.
English: M1 is not a CYP1A2 inducer.
Croatian: M1 nije induktor CYP1A2.
English: In the pivotal ENGOT-OV16 study, adverse reactions (ADRs) occurring ≥ 10 % of patients receiving Zejula monotherapy were nausea, thrombocytopenia, fatigue/asthenia, anaemia, constipation, vomiting, abdominal pain, neutropenia, insomnia, headache, decreased appetite, nasopharyngitis, diarrhoea, dyspnea, hypertension, dyspepsia, back pain, dizziness, cough, urinary tract infection, arthralgia, palpitations, and dysgeusia.
Croatian: U pivotalnom ispitivanju ENGOT-OV16 nuspojave koje su se javile u ≤ 10 % bolesnika koji su primali lijek Zejula u monoterapiji bile su mučnina, trombocitopenija, umor/astenija, anemija, konstipacija, povraćanje, abdominalna bol, neutropenija, nesanica, glavobolja, smanjen apetit, nazofaringitis, proljev, dispneja, hipertenzija, dispepsija, bol u leđima, omaglica, kašalj, infekcije mokraćnog sustava, artralgija, palpitacije i disgeuzija.
English: In repeat-dose oral toxicity studies, niraparib was administered daily for up to 3 months' duration in rats and dogs.
Croatian: U ispitivanjima toksičnosti ponovljenih doza primijenjenih peroralno, niraparib se primjenjivao svakodnevno u trajanju do 3 mjeseca u štakora i pasa.
English: Table 3: Adverse drug reactions: frequencies based on all-causality adverse events* System Organ Class
Croatian: Tablica 3: Nuspojave lijeka: učestalosti temeljene na štetnim događajima bilo kojeg uzroka* Organski sustav
English: Febrile neutropenia was reported in 2 out of 367 patients in the NOVA trial leading to the frequency uncommon.
Croatian: Febrilna neutropenija zabilježena je u 2 od 367 slučajeva u ispitivanju NOVA, čime se svrstava u učestalost „manje često“.
English: Signs may include fever, chills, feeling weak or confused, cough, pain or burning feeling when passing urine.
Croatian: Znakovi mogu uključivati vrućicu, zimicu, osjećaj slabosti ili zbunjenosti, kašalj, bol ili osjećaj pečenja prilikom mokrenja.
English: To be eligible for niraparib treatment, the patient should be in response (CR or PR) following completion of last platinum based chemotherapy.
Croatian: Kako bi bili pogodni za liječenje niraparibom bolesnici su morali biti u odgovoru (CR ili PR) nakon završetka posljednje kemoterapije koja je sadržavala platinu.
English: Population pharmacokinetic analyses indicated that age, weight and race had no significant impact on the pharmacokinetics of niraparib.
Croatian: Analize populacijske farmakokinetike pokazale su da dob, tjelesna težina i rasa nemaju značajan učinak na farmakokinetiku nirapariba.
English: The experimental test was not able to discriminate which patients would or would not benefit from niraparib maintenance therapy.
Croatian: Eksperimentalnim testom se nije moglo razlučiti koji bi bolesnici mogli imati koristi od terapije održavanja niraparibom, a koji ne.
English: PARP inhibitors block an enzyme called poly [adenosine diphosphate-ribose] polymerase (PARP).
Croatian: PARP inhibitori blokiraju enzim koji se zove poli(adenozin difosfat riboza) polimeraza (PARP).
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Croatian: Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.
English: The recommended starting dose is 3 capsules taken together once a day (total daily dose of 300 mg), with or without food.
Croatian: Preporučena početna doza je 3 kapsule uzete jedna za drugom, jednom na dan (ukupna doza od 300 mg), s hranom ili bez nje.
English: If adverse reactions are not manageable with this strategy of dose interruption and reduction, it is recommended that Zejula be discontinued.
Croatian: Ako se nuspojave ne mogu zbrinuti ovom strategijom prekidanja uzimanja i smanjenja doze, preporučuje se ukidanje lijeka Zejula.
English: Within each cohort, patients were randomised using a 2:1 allocation of niraparib and placebo.
Croatian: U svakoj skupini bolesnici su randomizirani u odnosu 2:1 kako bi im se dodijelio niraparib i placebo.
English: Following a signal regarding sepsis with niraparib, a number of relevant cases were identified.
Croatian: Praćenjem signala sepse koja se javljala uz niraparib, uočen je određen broj relevantnih slučajeva.
English: Your doctor will test your blood regularly throughout your treatment.
Croatian: Vaš će Vam liječnik redovito provjeravati krvnu sliku tijekom liječenja.
English: The most common serious adverse reactions > 1 % (treatment-emergent frequencies) were thrombocytopenia and anaemia.
Croatian: Najčešće ozbiljne nuspojave > 1 % (učestalosti zabilježene tijekom liječenja) bile su trombocitopenija i anemija.
English: • Swelling in the feet, ankles, legs, and/or hands
Croatian: • oticanje stopala, gležnjeva, nogu i/ili šaka
English: In pooled samples collected over 6 days, 40.0 % of the dose was recovered in the urine primarily as metabolites and 31.6 % of the dose was recovered in the feces primarily as unchanged niraparib.
Croatian: U zbirnim uzorcima, prikupljanima tijekom 6 dana, u urinu je pronađeno 40,0 % doze i to primarno u obliku metabolita, a 31,6 % doze pronađeno je u fecesu, primarno kao nepromijenjeni niraparib.
English: Uncommon (may affect up to 1 in 100 people) • Reduction in the number of red blood cells, white blood cells and platelets
Croatian: Manje često (mogu se javiti u do 1 na 100 osoba) • smanjenje broja crvenih krvnih stanica, bijelih krvnih stanica i trombocita
English: 84 × 1 hard capsules 56 × 1 hard capsules 28 × 1 hard capsules
Croatian: 84 × 1 tvrda kapsula 56 × 1 tvrda kapsula 28 × 1 tvrda kapsula
English: If MDS and/or AML are confirmed while on treatment with Zejula, treatment should be discontinued and the patient treated appropriately.
Croatian: Ako se tijekom liječenja lijekom Zejula potvrdi MDS i/ili AML, liječenje treba prekinuti te bolesnika odgovarajuće liječiti.
English: Increased plasma concentrations of co-administered medicinal products that are substrates of these transporters (e.g. metformin) cannot be excluded.
Croatian: Povećane koncentracije istodobno primijenjenih lijekova koji su supstrati tih prijenosnika (npr. metformina) u plazmi ne mogu se isključiti.
English: Gamma-glutamyl transferase increased, AST increased, blood creatinine increased, ALT increased, blood alkaline phosphatase increased, weight decreased
Croatian: Povišena gama-glutamil transferaza, povišen AST, povišen kreatinin u krvi, povišen ALT, povišena alkalna fosfataza u krvi, smanjena tjelesna težina